BioForce Nanosciences Holdings, Inc.
BFNH
$1.79
$0.010.56%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -3.83% | -0.08% | 2.87% | 5.98% | 4.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.83% | -0.08% | 2.87% | 5.98% | 4.32% |
| Operating Income | 3.83% | 0.08% | -2.87% | -5.98% | -4.32% |
| Income Before Tax | 64.50% | -163.62% | -169.39% | -175.46% | -173.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 64.50% | -163.62% | -169.39% | -175.46% | -173.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 64.50% | -163.62% | -169.39% | -175.46% | -173.98% |
| EBIT | 3.83% | 0.08% | -2.87% | -5.98% | -4.32% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 66.59% | -136.31% | -144.85% | -153.70% | -154.94% |
| Normalized Basic EPS | 12.75% | 10.58% | 4.90% | -1.00% | -2.00% |
| EPS Diluted | 66.59% | -136.31% | -144.85% | -153.70% | -154.94% |
| Normalized Diluted EPS | 12.75% | 10.58% | 4.90% | -1.00% | -2.00% |
| Average Basic Shares Outstanding | 11.68% | 13.43% | 9.80% | 6.17% | 2.54% |
| Average Diluted Shares Outstanding | 11.68% | 13.43% | 9.80% | 6.17% | 2.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |